The Regulatory Interface of ATMPs and Medical Devices in Europe

Ilona Reischl, PhD
BASG/AGES - Federal Office for Safety in Health Care
Austrian Agency for Health and Food Safety
Institute Surveillance
Traisengasse 5, 1200 Vienna, Austria
Disclaimer

- **EMA**: “The views expressed in this presentation are my personal views and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.”

- **BASG/AGES**: “The views expressed in this presentation are my personal views and may not be understood or quoted as being made on behalf of or reflecting the position of the Austrian Competent Authority.”
ATMPs and medical devices in the EU
Legislation and interfaces

ATMPs
- Dir/2001/83/EC ... Medicines
- Reg/726/2004/EC ... EMA/centr. MAA
- Reg/1394/2007/EC ... ATMP
- Reg/2014/536/EC ... ClinTrial

Co-development

Medical devices
- Reg/2017/745/EC ... devices
  Incorporates Clinical investigation requirements
- Reg/2017/746/EC ... IVDs
  Incorporates performance study requirements

Legal, Procedural and Scientific Interfaces
ATMPs and medical devices

Not all ATMP device combinations are “combined ATMPs”

Combined ATMP according to ATMP Regulation definition

- ATMP has one or more integral medical devices (MDs) or active implantable MDs components in scope the EU medical device legislation (integral - single integral product, intended exclusively for use in the given combination, not reusable)
  
  *example: viral vector in prefilled syringe*

ATMP with non-integral devices (co-packaged, referenced) ≠ combined ATMP

- A medicinal product with non-integral medical device(s) necessary for administration, correct dosing or use
  
  *example: cartridge co-packed with an automated mini-doser*

ATMP to be used with a referenced (not co-packaged) medical device (← SmPC)

*example: ATMP to be used with a dedicated surgical tool, e.g. syringe applying precise low volumes*
What is an integral device?

**In the context of EU medicinal products/ATMPs**

- What matters is the presentation of the product at the moment of the placing on the market, not at the time of administration → 3 cumulative conditions

  1. the device and the medicinal product form a single integral product
  2. intended exclusively for use in the given combination
  3. which is not reusable

**ATMPs:** Annex I to Directive 2001/83/EC clarifies that combination of the medical device with the cells at the time of administration can be considered as an integral part of the finished product.
Medical devices for manufacture

Relevance of the CE mark

- Medical devices for manufacture are not integral medical devices
- If equipment used to isolate/manipulate cells/tissues is CE marked as medical device, this applies only to a specific intended use, e.g. "separation of cells"
- The CE mark cannot apply to the resulting product, which is a cell based medicinal product ← immanent pharmacologic, immunologic, metabolic action
- → The user of the device becomes the manufacturer of a medicinal product → lack of awareness with users
- Technologic advances permit substantial manipulation → gene therapy in a private practice setting is technologically feasible
## Legal responsibilities for authorities in the EU

### ATMPs and devices

<table>
<thead>
<tr>
<th>Development (trials)</th>
<th>NCA - medicines</th>
<th>NCA - devices</th>
<th>*</th>
<th>Ethics committee</th>
</tr>
</thead>
</table>

*Clinical study lifecycle, inspections*

<table>
<thead>
<tr>
<th>Authorization/Certification</th>
<th>EMA</th>
<th>Notified Body</th>
</tr>
</thead>
</table>

*License Certification*

<table>
<thead>
<tr>
<th>Post-Authorization/Certification</th>
<th>EMA</th>
<th>Notified Body</th>
</tr>
</thead>
</table>

*Vigilance / post-marketing oversight, inspections*

*One or more entities*
Which Notified Body?

Whose responsibility?

- The responsible National Competent Authority for Clinical trials is determined by the location (e.g. responsible member state)
- ATMPs undergo mandatory centralized marketing Authorization → EMA/CAT
- The choice of Notified Body is up to the developer and not determined by location

An MAA applicant for a combined ATMP ...

- is requested to identify a NB in the Application form even in the case where NB assessment of the device component has not yet taken place
- should ensure this NB is notified for assessment of the type of device in the combined ATMP ← consider the experience of that NB with similar products
Procedural aspects during development

The European Legislation currently does not facilitate the simultaneous investigation of medicine and medical device/IVD in a single process.

<table>
<thead>
<tr>
<th>Goal of the investigation</th>
<th>EU Framework</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigational medicinal product</td>
<td>Clinical trial (CTR)</td>
</tr>
<tr>
<td>Investigational/non CE marked medical device</td>
<td></td>
</tr>
<tr>
<td>Integral device - Art. 1(9) MDR</td>
<td>Clinical trial (CTR)</td>
</tr>
<tr>
<td>Non-integral device (co-packaged)</td>
<td>Clinical investigation (MDR)</td>
</tr>
<tr>
<td>„Referenced“ administration device</td>
<td>Clinical investigation (MDR)</td>
</tr>
<tr>
<td>Investigational/non CE marked IVD</td>
<td>Performance study (IVDR)</td>
</tr>
</tbody>
</table>

→ One project could have multiple reporting requirements, potentially to different agencies and member states.
**Procedural aspects at Marketing Authorization**

ATMPs versus other medicinal products

- **Medicinal product**
  - Non-ATMP
    - **Integral device**
      - CE marked
      - Consultation with Notified Body
        - Art. 117 MDR → replacing Annex I point 12, Section 3.2. Dir 2001/83/EC
  - Non-CE marked
    - Consultation with Notified Body

- **Medicinal product**
  - ATMP
    - **Integral device**
      - CE marked
      - Consultation with Notified Body
        - Art. 9 Regulation (EC) No 1394/2007
    - Non-CE marked
      - CE mark required for introduction to the market

* CE-marked = CE marked for the intended use
Note, the slide is simplified and does not consider legal exceptions
Article 9 REG (EC) No 1394/2007

Consultation of a Notified Body - When and how?

- CAT to decide that NB consultation is needed
- NB assessment on the device part, if presented at MAA to be recognized
- When required it likely in the form of a list of questions

- When is it potentially needed?
  - When existing NB opinion relates to a different intended use
  - When the combination with the ATMP may have an effect on the original technical, clinical and biological characteristics of the device → focus on safety and performance of the device part
The consultation process

Communication according to art. 9 REG (EC) No 1394/2007

Any interaction between EMA/CAT and the NB(s) will be done in conjunction with the applicant ➔
Always to be involved/copied/informed.
However, for expediency, communication may be sent directly from EMA/CAT to the relevant NB.
Scenario 1: Consultation of NBs to get the results of the assessment of medical device(s)

To be revisited

Adapted from M-H. Pinheiro/EMA 2010
Device aspects and ATMPs

Scientific requirements

- Requirements related to medical device component(s) of combined ATMPs are detailed in ATMP specific guidelines.

- Where ATMP specific guidelines do not indicate the location of the relevant information in the MAA, the principles of the “Guideline on quality documentation for medicinal products when used with a medical device” should be followed.
  - Medical devices that are co-packaged with ATMPs.
  - Separately obtained devices which are referenced in the Product Information, because of their potential impact on the quality, safety and/or efficacy of the ATMP.

- Information on medical devices used during surgical procedures for application, implantation or administration of an ATMP which may impact on efficacy or safety as per Annex I, Part IV, Section 5.2.1 of Annex Dir2001/83/EC is expected in Module 5.
# Investigational ATMPs

## Guideline on Q, NC and C requirements

<table>
<thead>
<tr>
<th>Keywords</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigational ATMPs, gene therapy medicinal product, cell therapy medicinal product, tissue engineered product, exploratory trial, first in human trial, confirmatory trial</td>
<td>This guideline provides guidance on the structure and format of documents for a clinical trial application for exploratory and confirmatory trials with advanced therapy investigational medicinal products.</td>
</tr>
</tbody>
</table>

Medical device aspects considered

Interface activities

Not ATMP specific, but with CAT engagement

**Development** → see EudraLex Volume 10

- Q&A on Complex clinical trials (May 2022)
- Q&A on the interface between Regulation (EU) 536/2014 on clinical trials for medicinal products for human use (CTR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)

**Marketing Authorization**

- ATMP-specific Guidance documents
- Guideline on quality documentation for medicinal products when used with a medical device (EMA/CHMP/QWP/BWP/259165/2019)
- Focus group on provision of scientific advice for medicinal product developments comprising of drug-device combinations and drug-companion diagnostic combinations
Thank you for your attention
Questions?